Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 128c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of $0.87, $1.28 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $80 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Rocket Lab launches U.S. Space Force mission in record 16 hours
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield